Search | Clinical Trials Finder

Conditions: Spinal Cord Injuries, Neuropathic Pain
Interventions: Gabapentin, No gabapentin; Drug · Other
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions: DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 12 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2034
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumor, DLBCL
Interventions: RNK05047; Drug
Lead sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia • Louisville, Kentucky • New York, New York

Conditions: Diet, Healthy, Weight Change, Body, Dyslipidemias, Blood Pressure
Interventions: Fasting; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pancreas Cancer, Pancreas Adenocarcinoma
Interventions: Capecitabine; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Melanoma
Interventions: Fibrin Sealant; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: GU Research Network, LLC; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pelvic Ring Fractures
Interventions: Miacalcin Calcitonin Salmon Nasal Spray; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 65 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Colorectal Cancer Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions: ENCORE; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Biliary Tract Cancer, Biliary Tract Neoplasms
Interventions: Nivolumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia

Conditions: Large Granular Lymphocytic Leukemia, LGL Leukemia
Interventions: Cyclosporine, Gene expression analysis, Microarray analysis, Laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: insulin aspart, insulin detemir; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma
Interventions: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years to 60 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
Interventions: Hiltonol; Biological
Lead sponsor: Oncovir, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more

Conditions: Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
Interventions: olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar); Biological · Drug
Lead sponsor: Genelux Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 33
States / cities: Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more

Conditions: Head and Neck Cancer
Interventions: Pemetrexed plus Gemcitabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Histiocytic Neoplasms
Interventions: Ulixertinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Rochester, Minnesota • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Interventions: 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, TRU-016 6-20 mg/kg + idelalisib + rituximab, TRU-016 10-20 mg/kg + ibrutinib, TRU-016 10-20 mg/kg + bendamustine; Biological
Lead sponsor: Aptevo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 8
States / cities: Augusta, Georgia • Columbus, Ohio • Philadelphia, Pennsylvania + 4 more

Conditions: Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
Interventions: brentuximab vedotin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 8
States / cities: Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Arthritis, Rheumatoid
Interventions: adalimumab 40 mg, sirukumab 100 mg, sirukumab 50 mg, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Arvin, California + 39 more

Conditions: Lymphoma
Interventions: filgrastim, rituximab, Carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, yttrium Y 90 ibritumomab tiuxetan; Biological · Drug · Procedure + 1 more
Lead sponsor: Northwestern University; Other
Eligibility: 17 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota

Conditions: Non-small Cell Lung Cancer
Interventions: pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 19
States / cities: Los Angeles, California • Monterey, California • Orange, California + 14 more

Conditions: Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions: Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 154
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more

Conditions: Acute Ischemic Stroke, Cerebrovascular Disorders
Interventions: Registry; Other
Lead sponsor: Justin Fraser; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Effects of a Daily Time-Restricted Feeding Protocol on Diet Quality

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries

Early-Onset Colorectal Cancer Recurrence

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)

Ulixertinib in People With Histiocytic Neoplasms

Phase 1b Safety and Efficacy Study of TRU-016

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Brain, Blood And Clot or Tissue Registry And Collaboration